[Analysis of the results of treatment of multiple myeloma].
Therapeutic results were analysed in 62 cases of multiple myeloma treated by two-stage method: I. with cyclically non-specific agents (melphalan) in each case. When this treatment was a failure the second step was given: II. cyclically specific and non-specific agents by the M-2 schedule. Good therapeutic response was obtained in 70% of cases. The mean survival time in the whole group was 35 months, and in the subgroup with good prognosis it was 44 months. Most (74%) patients with IgG M-protein responded well to treatment with cyclically non-specific agents, while only 50% of those with IgA M-protein had a good response to them.
D000328:Adult; D000368:Aged; D000912:Antibodies, Neoplasm / Q000032:analysis; D003520:Cyclophosphamide / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D008297:Male; D008558:Melphalan / Q000008:administration & dosage*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality; D009194:Myeloma Proteins / Q000097:blood; D011241:Prednisone / Q000008:administration & dosage*; D011379:Prognosis; D013997:Time Factors; D014750:Vincristine / Q000008:administration & dosage*
D000912:Antibodies, Neoplasm; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D009194:Myeloma Proteins; D014750:Vincristine; D003520:Cyclophosphamide; D008558:Melphalan; D011241:Prednisone
Analiza wyników leczenia szpiczaka plazmocytowego.